{"entity":{"id":"nct07227402","kind":"trial","name":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","aka":["LITESPARK-033"],"tldr":"A phase 3 trial testing Zanzalintinib in renal cell carcinoma, now recruiting.","summary":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) is a phase 3 interventional study registered as NCT07227402, led by Merck Sharp & Dohme with Exelixis, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033). Planned enrolment is 904 participants (estimated). The study started in 2025-11-26 and primary completion is expected in 2032-02-27. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07227402","url":"https://clinicaltrials.gov/study/NCT07227402"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["zanzalintinib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07227402","phase":"3","setting":"A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)","sponsor":"Merck Sharp & Dohme","participation":[{"nct":"NCT07227402","source":"https://clinicaltrials.gov/study/NCT07227402","fetchedAt":"2026-10-07T16:55:34.394Z","studySha256":"7bbef7a0bc980efb4cec765012f82750468a6fa743314cef5baa328a07487521","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-03","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":904,"enrolmentType":"ESTIMATED","siteCount":127,"recruitingSiteCount":127,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Chile","Croatia","Czechia","Denmark","France","Germany","Greece","Hong Kong","Ireland","Italy","Mexico","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2025-11-26","startedType":"actual","enrolled":904,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07227402/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}